SCHEMBL8091695

SCHEMBL8091695

Nc1cc(C2(S(=O)(=O)C3CC3)CCCC2)nc(-c2ccc(NC(=O)NC3CC3)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
EPHX1 P07099 6/20 0.41
RAB9A P51151 4/20 0.41
PIK3CA P42336 3/20 0.41
MTOR P42345 3/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 3/20 0.39
KDR P35968 2/20 0.39
KIT P10721 1/20 0.39
FLT3 P36888 1/20 0.39
EPHX2 P34913 4/20 0.38
KLKB1 P03952 1/20 0.37
ALDH1A1 P00352 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8081909 0.98 CA12 (0.41) CA12CA1CA2CA9EPHX1
SCHEMBL8092188 0.93 PIK3CA (0.45) CA12CA1CA2CA9EPHX1
SCHEMBL8096200 0.91 EPHX1 (0.47) CA12CA1CA2CA9EPHX1
SCHEMBL8095567 0.90 PIK3CD (0.45) CA12CA1CA2CA9EPHX1
SCHEMBL8084603 0.89 PIK3CA (0.46) CA12CA1CA2CA9EPHX1
SCHEMBL8098306 0.88 CA12 (0.42) CA12CA1CA2CA9EPHX1
SCHEMBL8093447 0.88 MTOR (0.43) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL8091090 0.87 PIK3CD (0.45) CA12CA1CA2CA9PIK3CA
SCHEMBL8084799 0.86 PIK3CA (0.51) RAB9APIK3CAMTORPIK3CDPIK3CB
SCHEMBL8084016 0.86 CA12 (0.41) CA12CA1CA2CA9EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009007748-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2009-01-15 WO disclosed